Johnson & Johnson to acquire Atraverse Medical

April 30, 2026 - 19:17

Johnson & Johnson announced plans to acquire Atraverse Medical, a private company focused on tools for heart rhythm procedures. The deal, once finalized, will add several FDA-approved technologies to Johnson & Johnson's electrophysiology portfolio, which covers devices used to diagnose and treat irregular heartbeats.

Atraverse Medical develops systems that help doctors map the heart's electrical activity and deliver targeted therapy. The acquisition fits a broader push by Johnson & Johnson to strengthen its position in the fast-growing market for heart rhythm management. Electrophysiology procedures have been rising as more patients are diagnosed with conditions like atrial fibrillation.

Financial terms of the deal were not disclosed. Johnson & Johnson expects the transaction to close in the second quarter of 2025, pending regulatory approvals and other customary conditions. The company said the acquisition will support its long-term strategy of bringing new technologies to cardiologists and improving outcomes for patients with complex heart conditions.

Atraverse Medical's current management and staff are expected to join Johnson & Johnson's MedTech division after the deal closes. The move follows a string of similar acquisitions by Johnson & Johnson in the medical device space, as the company looks to expand beyond its traditional pharmaceutical and consumer health businesses.